MMCB plans to pay dividends for 9 months in the amount of 42.639 million rubles

56
2
AK&M 16 November 2026 15:22

PJSC International Medical Center for Biomaterials Processing and Cryopreservation (MMCB) plans to pay dividends for 9 months of 2026 for 42.639 million rubles at the rate of 2.33 rubles. per share. This is stated in the company's message following the meeting of the Board of Directors.

The shareholders will consider this issue at an extraordinary meeting, which will be held in absentia. The deadline for accepting voting ballots is December 18, 2026.

Recall that for 6 months of 2026, it was decided to pay dividends for 50.142 million rubles. 

The International Medical Center for the Processing and Cryopreservation of Biomaterials (MMCB (Gemabank)) is a biotechnology company, part of the Artgen Biotech group of companies, engaged in the personal storage of biomaterials, primarily hematopoietic stem cells, and the development of gene therapy drugs for the treatment of diseases of the blood and immune system.

MMCB's net profit under RAS for the first 9 months of 2026 decreased by 23% to 92.465 million rubles from 120.166 million rubles a year earlier. Revenue increased by 5% to RUB 294.195 million from RUB 280.324 million. Profit from sales decreased by 7% to RUB 127.3 million from RUB 136.33 million. Income from participation in other organizations amounted to 9 million rubles.

Gemabank paid dividends for 2025 in the amount of 2.8 rubles. per share and approved the payment of dividends for the first half of 2026 in the amount of 2.74 rubles. per share.

The volume of samples accepted for storage increased by 21% to 3,363 thousand.

Artgen is a biotech company with a portfolio of developments.

Gemabank and Nextgen remain the main sources of cash flow within the holding.

As of December 31, 2025, the main shareholders of PJSC Artgen are: individuals — 44.21%, LLC MirMam — 14.12%, LLC Artgen Ventures (formerly LLC HSCC Ventures) — 12.14%, PJSC MMTSB - 8.1%. The total share of the main shareholders in the authorized capital of the company is 78.56%.

Artgen Biotech's net profit in 2025 according to IFRS decreased by 55.35% to 107.68 million rubles from 241.16 million rubles a year earlier. Consolidated revenue increased by 12.8% to RUB 1.7 billion from RUB 1.5 billion. EBITDA fell by 33.23% to RUB 214.85 million from RUB 321.777 million.

Artgen Biotech's net profit in 2025 according to RAS increased by 14% to 303.6 million rubles from 265.45 million rubles a year earlier. Revenue increased to 361.435 million rubles from 119.861 million rubles, gross profit — to 350.129 million rubles from 66.3 million rubles.

Following its updated development strategy for 2024-2026, Artgen Biotech generates revenue from dividends from its subsidiaries.